All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference Listing
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Identifying the Link Between Breast Cancer and Obesity

Feb 11, 2014
Andrew J. Brenner, MD, PhD

Andrew J. Brenner, MD, PhD, assistant professor of medicine, clinical investigator, Cancer Therapy Research Center, The University of Texas Health Science Center, discusses a study that was conducted to try to find the link between obesity and breast cancer.

Andrew J. Brenner, MD, PhD, assistant professor of medicine, clinical investigator, Cancer Therapy Research Center, The University of Texas Health Science Center, discusses a study that was conducted to try to find the link between obesity and breast cancer.

Clinical Pearls:

  • Serum that was collected from a group of patients who had survived breast cancer was developed into an assay that would assess breast cancer growth
  • The serum was conditioned on adipose stromal cells before looking at the impact on breast cancer cells that were ER-positive
  • The serum collected from obese patients showed extra proliferation within the breast cancer cells
  • It was determined that inflammation, which is a known systemic problem in obesity, was turning on aromatase activity in obese patients with breast cancer ​
Related Videos
Related Content

RLY-2608 Induces Antitumor Activity in Patients With PIK3CA Mutations

May 25th 2023

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022

Barata on the Latest Updates in Metastatic Prostate Cancer

May 23rd 2023

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

September 25th 2020

Addressing Skin Cancer: From Screening to Treatment

May 20th 2023

Behind the FDA Approval: Subcutaneous Epcoritamab for R/R DLBCL

May 19th 2023

RLY-2608 Induces Antitumor Activity in Patients With PIK3CA Mutations

May 25th 2023

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022

Barata on the Latest Updates in Metastatic Prostate Cancer

May 23rd 2023

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

September 25th 2020

Addressing Skin Cancer: From Screening to Treatment

May 20th 2023

Behind the FDA Approval: Subcutaneous Epcoritamab for R/R DLBCL

May 19th 2023

RLY-2608 Induces Antitumor Activity in Patients With PIK3CA Mutations

May 25th 2023

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022

Barata on the Latest Updates in Metastatic Prostate Cancer

May 23rd 2023

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

September 25th 2020

Addressing Skin Cancer: From Screening to Treatment

May 20th 2023

Behind the FDA Approval: Subcutaneous Epcoritamab for R/R DLBCL

May 19th 2023
Related Content

RLY-2608 Induces Antitumor Activity in Patients With PIK3CA Mutations

RLY-2608 Induces Antitumor Activity in Patients With PIK3CA Mutations

May 25th 2023
Article

In an interview with Targeted Oncology, Andreas Varkaris, MD, PhD, discussed findings from the ReDiscover trial and treating patients with PIK3CA mutations.

Read More


Unpacking the New Recommendations for Early-Stage Breast Cancer Management

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022
Podcast

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Listen


Barata on the Latest Updates in Metastatic Prostate Cancer

Barata on the Latest Updates in Metastatic Prostate Cancer

May 23rd 2023
Article

In an interview with Targeted Oncology, Pedro Barata, MD, MSc, discussed the current therapies available, unmet needs, and ongoing studies for patients with metastatic prostate cancer.

Read More


Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

September 25th 2020
Podcast

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Listen


Addressing Skin Cancer: From Screening to Treatment

Addressing Skin Cancer: From Screening to Treatment

May 20th 2023
Article

In an interview with Targeted Oncology, Meredith McKean, MD, MPH of Sarah Cannon Research Institute reviewed the recent changes to the U.S. Preventive Services Task Force skin cancer screening guidelines, and discussed advances in the skin cancer treatment paradigm for those who could not prevent the disease.

Read More


Behind the FDA Approval: Subcutaneous Epcoritamab for R/R DLBCL

Behind the FDA Approval: Subcutaneous Epcoritamab for R/R DLBCL

May 19th 2023
Article

In an interview with Targeted Oncology, Tycel Phillips, MD, discussed what led to the FDA approval of subcutaneous epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma and how it adds to the current treatment landscape.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.